Retroperitoneal fibrosis.
Vaglio A, Salvarani C, Buzio C.
Lancet. 2006 Jan 21;367(9506):241-51. doi: 10.1016/S0140-6736(06)68035-5.
Risk of nephrogenic systemic fibrosis (NSF) in oncology patients receiving gadoxetic acid and updated risk of estimate of NSF in patients receiving gadoxetic acid with moderate and severe renal impairment.
Gauthier ID, Macleod CA, Sathiadoss P, McGrath TA, Nair V, Schieda N.
Abdom Radiol (NY). 2022 Mar;47(3):1196-1201. doi: 10.1007/s00261-021-03367-3. Epub 2022 Jan 7.
Renal function, nephrogenic systemic fibrosis and other adverse reactions associated with gadolinium-based contrast media.
Canga A, Kislikova M, Martínez-Gálvez M, Arias M, Fraga-Rivas P, Poyatos C, de Francisco AL.
Nefrologia. 2014;34(4):428-38. doi: 10.3265/Nefrologia.pre2014.Apr.12375.
T Cells in Fibrosis and Fibrotic Diseases.
Zhang M, Zhang S.
Front Immunol. 2020 Jun 26;11:1142. doi: 10.3389/fimmu.2020.01142. eCollection 2020.
Nephrogenic systemic fibrosis: an emerging threat among renal patients.
DeHoratius DM, Cowper SE.
Semin Dial. 2006 May-Jun;19(3):191-4. doi: 10.1111/j.1525-139X.2006.00152.x.
The Fibrosis and Immunological Features of Hypochlorous Acid Induced Mouse Model of Systemic Sclerosis.
Meng M, Tan J, Chen W, Du Q, Xie B, Wang N, Zhu H, Wang K.
Front Immunol. 2019 Aug 20;10:1861. doi: 10.3389/fimmu.2019.01861. eCollection 2019.
Nephrogenic systemic fibrosis.
Kaewlai R, Abujudeh H.
AJR Am J Roentgenol. 2012 Jul;199(1):W17-23. doi: 10.2214/AJR.11.8144.
Gadolinium-Induced Fibrosis.
Todd DJ, Kay J.
Annu Rev Med. 2016;67:273-91. doi: 10.1146/annurev-med-063014-124936.
Nephrogenic Systemic Fibrosis in the Setting of Transient Renal Insufficiency.
Dinh H, Phan J, Lountzis NI, Purcell SM.
Cutis. 2021 Dec;108(6):342-344. doi: 10.12788/cutis.0410.
Nephrogenic systemic fibrosis.
Bardin T, Richette P.
Curr Opin Rheumatol. 2010 Jan;22(1):54-8. doi: 10.1097/BOR.0b013e328333bf3d.
